Pharmacokinetics and neurotropic effects of cyclo-L-prolylglycine and its modified analogues

The review presents the results of studies on pharmacokinetics, metabolism, and bioavailability new neurotropic dipeptide cyclo-Lprolilglycine (CPG) their pharmacological activity. It was shown that pharmacologically active metabolite nootropic drug noopept is an endogenous dipeptide, it a fragment terminal Tripeptide insulin-like nerve growth factor IGF-1. Much attention paid both in Russia abroad to development modified CPG analogues with improved pharmacokinetic properties, enzymatically more stable, better penetrating BBB, highly effective when used micromolar doses. shows neuroprotective activity ischemic-hypoxic other brain injuries, addition, has complex effects therefore can be considered not only as potential drug, but also basic structure for drugs – analogs greater enzymatic resistance higher central nervous system.